adhesion molecule with Ig like domain 3Genealiases: ALI3 · AMIGO-3
Q-omics provides the consensus-scored AMIGO3 profile across patient tissues and cancer cell-line models. AMIGO3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, AMIGO3 is differentially expressed in 7, with the highest sampling consensus in BLCA. Additionally, AMIGO3 RNA expression shows 12,517 significant gene co-expression associations, with the highest sampling consensus in SCLC. Together, these results highlight DLBC, BLCA, and SCLC as cancer lineages where AMIGO3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AMIGO3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AMIGO3 survival associations across molecular data types. AMIGO3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AMIGO3 RNA expression–survival associations across cancer types. High AMIGO3 expression shows unfavorable associations in DLBC, LGG, ACC and KIRC, but favorable associations in HNSC and KIRP. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify DLBC as the clearest survival context for AMIGO3 RNA expression.
This table summarizes AMIGO3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for AMIGO3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AMIGO3 shows higher tumor expression in BLCA, COAD, BRCA, LIHC, STAD and LUAD. The BLCA box plot shows higher AMIGO3 RNA expression in tumor versus normal tissue (log2 FC = +0.034, t-test p = .010).
This table shows molecular features associated with AMIGO3 in patient tissues and cancer cell lines. In patient samples, AMIGO3 shows the broadest associations at the RNA and protein expression levels, with SCLC recurring as the lineage with the largest associated feature set. In cancer cell lines, AMIGO3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
